This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock KOOL vs. THMO, MDXH, EUDA, ONCY, BHST, HURA, CNTB, SAVA, ACTU, and ANIXShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), MDxHealth (MDXH), EUDA Health (EUDA), Oncolytics Biotech (ONCY), BioHarvest Sciences (BHST), TuHURA Biosciences (HURA), Connect Biopharma (CNTB), Cassava Sciences (SAVA), Actuate Therapeutics (ACTU), and ANIXA BIOSCIENCES (ANIX). These companies are all part of the "medical" sector. Cesca Therapeutics vs. Its Competitors ThermoGenesis MDxHealth EUDA Health Oncolytics Biotech BioHarvest Sciences TuHURA Biosciences Connect Biopharma Cassava Sciences Actuate Therapeutics ANIXA BIOSCIENCES ThermoGenesis (NASDAQ:THMO) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do institutionals & insiders hold more shares of THMO or KOOL? 5.8% of ThermoGenesis shares are held by institutional investors. Comparatively, 3.1% of Cesca Therapeutics shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by company insiders. Comparatively, 68.9% of Cesca Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is THMO or KOOL more profitable? ThermoGenesis has a net margin of 0.00% compared to Cesca Therapeutics' net margin of -98.84%. ThermoGenesis' return on equity of 0.00% beat Cesca Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ThermoGenesisN/A N/A N/A Cesca Therapeutics -98.84%-77.30%-37.75% Does the media prefer THMO or KOOL? In the previous week, ThermoGenesis had 1 more articles in the media than Cesca Therapeutics. MarketBeat recorded 1 mentions for ThermoGenesis and 0 mentions for Cesca Therapeutics. ThermoGenesis' average media sentiment score of 0.00 equaled Cesca Therapeutics'average media sentiment score. Company Overall Sentiment ThermoGenesis Neutral Cesca Therapeutics Neutral Which has more volatility & risk, THMO or KOOL? ThermoGenesis has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Which has better earnings and valuation, THMO or KOOL? ThermoGenesis has higher earnings, but lower revenue than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioThermoGenesis$9.61M0.00-$17.98M-$5.140.00Cesca Therapeutics$9.67M2.97-$39.72M-$3.60-3.30 SummaryThermoGenesis beats Cesca Therapeutics on 9 of the 12 factors compared between the two stocks. Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.74M$105.01M$5.47B$9.53BDividend Yield0.50%N/A4.74%4.08%P/E Ratio-3.305.8328.6723.80Price / Sales2.970.48422.3188.12Price / CashN/A45.3035.4557.96Price / Book3.822.708.275.55Net Income-$39.72M$18.75M$3.24B$259.03M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$11.89-1.3%N/A+14.6%$28.74M$9.67M-3.3053THMOThermoGenesis0.2298 of 5 starsN/AN/A-99.9%$1K$9.61M0.0040MDXHMDxHealth2.7999 of 5 stars$2.42-0.4%$7.00+189.3%-12.3%$114.91M$90.05M-2.10300Positive NewsEUDAEUDA Health0.9488 of 5 stars$3.02-2.3%N/A-14.6%$114.81M$4.01M0.002Gap DownONCYOncolytics Biotech2.2907 of 5 stars$1.24+2.5%$4.33+249.5%-3.9%$114.08MN/A-4.2830Upcoming EarningsBHSTBioHarvest SciencesN/A$6.90+0.9%$13.67+98.1%N/A$112.35M$25.19M-13.80N/AHURATuHURA Biosciences1.2746 of 5 stars$2.74+7.5%$12.67+362.3%N/A$111.39MN/A0.00N/AGap DownCNTBConnect Biopharma2.9786 of 5 stars$2.38+19.0%$7.00+194.1%+73.9%$111.12M$26.03M0.00110Short Interest ↑High Trading VolumeSAVACassava Sciences3.5719 of 5 stars$2.58+12.2%$54.50+2,012.4%-91.0%$111.11MN/A-1.7230ACTUActuate Therapeutics1.9823 of 5 stars$6.26+10.6%$20.50+227.5%N/A$111.05MN/A0.0010News CoverageANIXANIXA BIOSCIENCES3.2883 of 5 stars$3.34-2.6%$9.00+169.5%-11.2%$110.48M$210K-8.795 Related Companies and Tools Related Companies THMO Alternatives MDXH Alternatives EUDA Alternatives ONCY Alternatives BHST Alternatives HURA Alternatives CNTB Alternatives SAVA Alternatives ACTU Alternatives ANIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOOL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KOOL Stock Alerts